Literature DB >> 15542729

Neuromechanism of developing methamphetamine psychosis: a neuroimaging study.

Masaomi Iyo1, Yoshimoto Sekine, Norio Mori.   

Abstract

The long-term use of methamphetamine (MAP) induces a psychotic state, called MAP psychosis. To understand the neuromechanisms of the persistent psychosis, we used SPECT, MR spectroscopy (MRS), and PET on the MAP users. The SPECT study showed a high incidence of multiple patchy deficits in cerebral blood flow among the users. The MRS study MAP users showed a significantly reduced ratio of creatine plus phosphocreatine (Cr + PCr)/choline-containing compounds (Cho) in the brain compared with the healthy control subjects. In addition, the reduction in the ratio of Cr + PCr/Cho was significantly correlated with the duration of MAP use and with the severity of residual psychiatric symptoms. PET revealed no significant differences between the ex-users of MAP and the healthy controls in the density of striatal dopamine D2 receptors. On the other hand, the density of dopamine transporter in the nucleus accumbens and caudate/putamen in the MAP users was significantly less compared with the controls. This reduction was significantly correlated with the length of use and severity of psychotic symptoms. These findings suggest that long-term use of MAP causes abnormal cerebral blood flow patterns, reduction of brain dopamine transporter density, and metabolite alteration, which may be closely related to a susceptibility to MAP psychosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15542729     DOI: 10.1196/annals.1316.036

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

Review 1.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 3.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

4.  Behavioral regulation in methamphetamine abusers: an fMRI study.

Authors:  Ruth Salo; Catherine Fassbender; Michael H Buonocore; Stefan Ursu
Journal:  Psychiatry Res       Date:  2012-11-10       Impact factor: 3.222

5.  Enhanced midbrain response at 6-month follow-up in cocaine addiction, association with reduced drug-related choice.

Authors:  Scott J Moeller; Dardo Tomasi; Patricia A Woicik; Thomas Maloney; Nelly Alia-Klein; Jean Honorio; Frank Telang; Gene-Jack Wang; Ruiliang Wang; Rajita Sinha; Deni Carise; Janetta Astone-Twerell; Joy Bolger; Nora D Volkow; Rita Z Goldstein
Journal:  Addict Biol       Date:  2012-03-28       Impact factor: 4.280

6.  Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction.

Authors:  Sharanya M Kousik; Steven M Graves; T Celeste Napier; Chaohui Zhao; Paul M Carvey
Journal:  Neuroreport       Date:  2011-12-07       Impact factor: 1.837

Review 7.  Methamphetamine toxicity and its implications during HIV-1 infection.

Authors:  Peter S Silverstein; Ankit Shah; Raeesa Gupte; Xun Liu; Robert W Piepho; Santosh Kumar; Anil Kumar
Journal:  J Neurovirol       Date:  2011-07-23       Impact factor: 2.643

8.  Decreased frontal lobe phosphocreatine levels in methamphetamine users.

Authors:  Young-Hoon Sung; Deborah A Yurgelun-Todd; Xian-Feng Shi; Douglas G Kondo; Kelly J Lundberg; Erin C McGlade; Tracy L Hellem; Rebekah S Huber; Kristen K Fiedler; Renee E Harrell; Bethany R Nickerson; Seong-Eun Kim; Eun-Kee Jeong; Perry F Renshaw
Journal:  Drug Alcohol Depend       Date:  2012-10-18       Impact factor: 4.492

Review 9.  Management of methamphetamine abuse and dependence.

Authors:  Walter Ling; Richard Rawson; Steve Shoptaw; Walter Ling
Journal:  Curr Psychiatry Rep       Date:  2006-10       Impact factor: 8.081

Review 10.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.